Navigation Links
Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing
Date:1/26/2009

> isolates were 0.06, 0.12, and 4 micrograms/mL, respectively. Delafloxacin's MIC90 values against all MRSA including the quinolone-resistant MRSA strains was also 0.06 micrograms/mL.

"We are extremely encouraged by the final results of this third Phase 2 trial, which affirm delafloxacin's safety and show its broad spectrum activity in difficult-to-treat complicated skin infections," said Susan Froshauer, Ph.D., President and CEO of Rib-X Pharmaceuticals. "Delafloxacin proved to be the more active compound compared to tigecycline when evaluated against both Gram-positive and Gram-negative bacterial isolates from patients, including MRSA and quinolone-resistant MRSA and other organisms. Additionally, this drug has the potential for IV use in the hospital with an oral step down."

"Rib-X starts off 2009 extremely well positioned to proceed with advancing delafloxacin towards Phase 3 trials," continued Dr. Froshauer. "We not only have excellent Phase 2 results for one of our key compounds, but we also have the commitment of our investors, and we would like to thank them for their continued support."

Phase 2 Study Design and Results

This Phase 2 double-blind study evaluated the safety and efficacy of delafloxacin at two intravenous doses, 300 mg BID and 450 mg BID, compared to tigecycline (TYGACIL(R), Wyeth Pharmaceuticals), in adults with cSSSI. Treatment duration was 5 to 14 days. Of the 150 patients randomized in this trial, 68% were male; the mean age was 40+/-14.5 years. 36% had cellulitis, 31% had wound infections and 33% had abscesses. 111 (74%) patients had pathogens identified at baseline, with 96 identified as S. aureus.

The clinical cure rates in the Clinically Evaluable and Modified Intent-to-Treat populations are presented below:

                       Percent Clinical Cure at TOC
    Population      DFX 300 mg BID      DFX 450 m
'/>"/>
SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rib-X Pharmaceuticals to Present at the 2008 ICAAC/IDSA Joint Meeting
2. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
3. Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institutes 2nd Annual Challenge of Antibacterial Development Conference
4. Rib-X Pharmaceuticals Initiates Two Phase 2 Studies for Novel Antibiotic Compound RX-1741
5. MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine
6. Axikin Pharmaceuticals Spins out of Actimis
7. BioMed Realty Trust Extends Leases With Vertex Pharmaceuticals Through 2015
8. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
9. Cumberland Pharmaceuticals Appoints Lee Product Director
10. Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
11. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor management ... safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... York, NY (PRWEB) , ... July 30, 2015 , ... As part of its 2015 ... raw material and technical service business units, Whitehouse Laboratories is pleased to ... will be adjacent to the Container Center of Excellence and will be strictly dedicated to ...
(Date:7/29/2015)... According to a new market research ... Forecasts (2015-2020), , published by Mordor Intelligence, the Global market ... end of 2020, with North America ... of the global market size. The Global market for Stem ... during the period of (2015-2020).      (Logo: http://photos.prnewswire.com/prnh/20150428/740799) ...
(Date:7/29/2015)... Ala., July 29, 2015  HealthSouth ... nation,s largest providers of post-acute healthcare services, offering ... its results of operations for the second quarter ... quarter was characterized by strong volume growth in ... Adjusted EBITDA," said Jay Grinney, President and Chief ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... , , Akira Ichikawa and Seiji Igarashi , ... , Introduction ... the most consistently , used mutation scanning methods. It ... be widely used particularly in gene diagnostic laboratories. , ...
... Axel Reinecke-Lthge*, Barbara Mllmann*, Angela , Kellner, ... of Pathology and Department of Hematopathology, Christian- , ... , ... the cause underlying many non-neoplastic , and ...
... Glenn A. Miller, Ph.D., Molecular Profiling Laboratory, Genzyme, ... Introduction , ... study of genes that play a role in the development ... single and multiple gene disorders. A wide variety of different , ...
Cached Biology Technology:Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 2Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System 3Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 2Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 3Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System 4A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 2A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 3A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 4A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 5A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 6A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 7A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis 8
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... , July 21, 2015 Today, ZTE announced ... received as well as expected revenues in 2015 that relate to ... communicated revenue guidance of approximately 2,200 MSEK for 2015. ... a leading smartphone manufacturer in China and ... 02 5 for Axon , ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2
... On April 15, 2010 , Dr. Stipkala joined a panel ... hosted by the University of South Carolina ,s NanoCenter in ... capitalists from all over the Southeast who are active in the nanotechnology ... Dr. Stipkala and ...
... Bethesda, MD The Genetics Society of America is ... selected for poster awards at the 51st Annual Drosophila ... were selected for first, second and third place awards ... undergraduate. This was the first time that undergraduate student ...
... YORK (April 25, 2010) -- Researchers at the ... Psychiatry at Weill Cornell Medical College discovered that ... behaviors. The genetically altered mice, which behaved much ... disorder (OCD), could help scientists design new therapies ...
Cached Biology News:Dr. Jeremy M. Stipkala, Patent Attorney, Speaks on USC NanoCenter Panel 2Genetics Society of America announces award recipients at 51st Annual Drosophila Conference 2Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 2Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 3Weill Cornell researchers find that a single gene is responsible for OCD-like behaviors in mice 4
... Our Smart Solutions has now entered ... Screening (HCS) by partnering up with Cellomics, ... from the integration of Beckman Coulter‘s automated ... uncovers deeper biological information at the sub-cellular ...
Immunogen GST fusion protein corresponding to full-length rat JNK3/ SAPK1b. Quality Assurance Routinely evaluated by immunoblot. Stability 2 years at -20°C from date of shipment GenBank A...
... demands on cell and tissue culture assumes ... Therefore, both cell concentration and percentage of ... precisely. The new Vi-CELLTM Cell Viability Analyzer ... to perform the trypan blue dye exclusion ...
... a post-translational modification that plays an ... immune regulation, inflammation, cell-to-cell adhesion, and ... two lectin based Glycoprotein Isolation Kits, ... Agglutinin (WGA), that allow isolation of ...
Biology Products: